1
|
Kårlund A, Paukkonen I, Gómez-Gallego C, Kolehmainen M. Intestinal Exposure to Food-Derived Protease Inhibitors: Digestion Physiology- and Gut Health-Related Effects. Healthcare (Basel) 2021; 9:1002. [PMID: 34442141 PMCID: PMC8394810 DOI: 10.3390/healthcare9081002] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/22/2021] [Accepted: 08/03/2021] [Indexed: 12/15/2022] Open
Abstract
Plant-derived protease inhibitors (PI), such as Bowman-Birk inhibitors and Kunitz-type inhibitors, have been suggested to negatively affect dietary protein digestion by blocking the activity of trypsin and chymotrypsin in the human gastrointestinal system. In addition, some PIs may possess proinflammatory activities. However, there is also scientific evidence on some beneficial effects of PIs, for example, gut-related anti-inflammatory and chemopreventive activities in vitro and in vivo. Some PIs are sensitive to processing and digestion; thus, their survival is an important aspect when considering their positive and negative bioactivities. The aim of this review was to evaluate the relevance of PIs in protein digestion in humans and to discuss the potential of PIs from whole foods and as purified compounds in decreasing symptoms of bowel-related conditions. Based on the reviewed literature, we concluded that while the complex interactions affecting plant protein digestibility and bioavailability remain unclear, PI supplements could be considered for targeted purposes to mitigate inflammation and gastric pain.
Collapse
Affiliation(s)
- Anna Kårlund
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; (C.G.-G.); (M.K.)
| | - Isa Paukkonen
- Institute of Biomedicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland;
| | - Carlos Gómez-Gallego
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; (C.G.-G.); (M.K.)
| | - Marjukka Kolehmainen
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; (C.G.-G.); (M.K.)
| |
Collapse
|
2
|
de Freitas MAG, Amaral NO, Álvares ADCM, de Oliveira SA, Mehdad A, Honda DE, Bessa ASM, Ramada MHS, Naves LM, Pontes CNR, Castro CH, Pedrino GR, de Freitas SM. Blood pressure-lowering effects of a Bowman-Birk inhibitor and its derived peptides in normotensive and hypertensive rats. Sci Rep 2020; 10:11680. [PMID: 32669617 PMCID: PMC7363796 DOI: 10.1038/s41598-020-66624-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 05/12/2020] [Indexed: 12/14/2022] Open
Abstract
Bioactive plant peptides have received considerable interest as potential antihypertensive agents with potentially fewer side effects than antihypertensive drugs. Here, the blood pressure-lowering effects of the Bowman-Birk protease inhibitor, BTCI, and its derived peptides, PepChy and PepTry, were investigated using normotensive (Wistar-WR) and spontaneously hypertensive rats (SHR). BTCI inhibited the proteases trypsin and chymotrypsin, respectively, at 6 µM and 40 µM, a 10-fold greater inhibition than observed with PepTry (60 µM) and PepChy (400 µM). These molecules also inhibited angiotensin converting enzyme (ACE) with IC50 values of 54.6 ± 2.9; 24.7 ± 1.1; and 24.4 ± 1.1 µM, respectively, occluding its catalytic site, as indicated by molecular docking simulation, mainly for PepChy and PepTry. Gavage administration of BTCI and the peptides promoted a decrease of systolic and diastolic blood pressure and an increase of renal and aortic vascular conductance. These effects were more expressive in SHR than in WR. Additionally, BTCI, PepChy and PepTry promoted coronary vasodilation and negative inotropic effects in isolated perfused hearts. The nitric oxide synthase inhibitor blunted the BTCI and PepChy, with no cardiac effects on PepTry. The findings of this study indicate a therapeutic potential of BTCI and its related peptides in the treatment of hypertension.
Collapse
Affiliation(s)
- Maria Alzira Garcia de Freitas
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil
| | - Nathalia Oda Amaral
- Center of Neuroscience and Cardiovascular Physiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil
| | - Alice da Cunha Morales Álvares
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil
| | - Sandriele Aires de Oliveira
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil
| | - Azadeh Mehdad
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil
| | - Diego Elias Honda
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil
| | - Amanda Sá Martins Bessa
- Integrative Laboratory of Cardiovascular and Neurological Pathophysiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil
| | - Marcelo Henrique Soller Ramada
- Graduate Program in Genomic Science and Biotechnology, and Graduate Program in Gerontology, Catholic University of Brasília, Brasília, DF, 70790-160, Brazil
| | - Lara Marques Naves
- Center of Neuroscience and Cardiovascular Physiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil
| | - Carolina Nobre Ribeiro Pontes
- Integrative Laboratory of Cardiovascular and Neurological Pathophysiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil
| | - Carlos Henrique Castro
- Integrative Laboratory of Cardiovascular and Neurological Pathophysiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil
| | - Gustavo Rodrigues Pedrino
- Center of Neuroscience and Cardiovascular Physiology; Department of Physiological Sciences, Biological Sciences Institute, Federal University of Goiás, Goiânia, GO, 74690-900, Brazil.
| | - Sonia Maria de Freitas
- Biology Institute, Department of Cell Biology, Laboratory of Biophysics, University of Brasília (UnB), Quadra 604, Asa Norte, Bloco J 1° andar, Brasília, DF, 70910-900, Brazil.
| |
Collapse
|
3
|
Olías R, Becerra-Rodríguez C, Soliz-Rueda JR, Moreno FJ, Delgado-Andrade C, Clemente A. Glycation affects differently the main soybean Bowman-Birk isoinhibitors, IBB1 and IBBD2, altering their antiproliferative properties against HT29 colon cancer cells. Food Funct 2019; 10:6193-6202. [PMID: 31501839 DOI: 10.1039/c9fo01421g] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Naturally-occurring serine protease inhibitors of the Bowman-Birk family, particularly abundant in legume seeds, exert their potential chemopreventive and/or therapeutic properties via protease inhibition. Processing of legume seeds, including soybeans, has been proposed as a major cause for their loss of bioactivity due to glycation. In order to assess how glycation affected the protease inhibitory activities of major soybean Bowman-Birk isoinhibitors (BBI) and their antiproliferative properties, IBB1 and IBBD2 were purified and subjected to glycation under controlled conditions using glucose at high temperature. Both soybean isoinhibitors showed remarkable heat stability. In the presence of glucose, IBBD2 lost most of its trypsin inhibitory activity while IBB1 maintains similar trypsin and chymotrypsin inhibitory activities as in the absence of sugar. Glycation patterns of both BBI proteins were assessed by MALDI-TOF spectrometry. Our results show that the glycation process affects IBBD2, losing partially its antiproliferative activity against HT29 colon cancer cells, while glycated-IBB1 was unaffected.
Collapse
Affiliation(s)
- Raquel Olías
- Estación Experimental del Zaidín (EEZ, CSIC), Profesor Albareda 1, Granada 18008, Spain.
| | | | - Jorge R Soliz-Rueda
- Estación Experimental del Zaidín (EEZ, CSIC), Profesor Albareda 1, Granada 18008, Spain.
| | - F Javier Moreno
- Instituto de Investigación en Ciencias de la Alimentación, (CIAL, CSIC-UAM), Nicolás Cabrera 9, Campus de Cantoblanco-Universidad Autónoma de Madrid, Madrid 28049, Spain
| | - Cristina Delgado-Andrade
- Instituto de Ciencia y Tecnología de los Alimentos y Nutrición (ICTAN, CSIC), Jose Antonio Novais 10, Madrid 28040, Spain
| | - Alfonso Clemente
- Estación Experimental del Zaidín (EEZ, CSIC), Profesor Albareda 1, Granada 18008, Spain.
| |
Collapse
|
4
|
Aranda-Olmedo I, Ruiz R, Peinado MJ, Rubio LA. A pea (Pisum sativum L.) seed albumin extract prevents colonic DSS induced dysbiosis in mice. J Funct Foods 2017. [DOI: 10.1016/j.jff.2017.05.038] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
5
|
|
6
|
Indarte M, Lazza CM, Assis D, Caffini NO, Juliano MA, Avilés FX, Daura X, López LMI, Trejo SA. A Bowman-Birk protease inhibitor purified, cloned, sequenced and characterized from the seeds of Maclura pomifera (Raf.) Schneid. PLANTA 2017; 245:343-353. [PMID: 27778107 DOI: 10.1007/s00425-016-2611-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 10/17/2016] [Indexed: 06/06/2023]
Abstract
A new BBI-type protease inhibitor with remarkable structural characteristics was purified, cloned, and sequenced from seeds of Maclura pomifera , a dicotyledonous plant belonging to the Moraceae family. In this work, we report a Bowman-Birk inhibitor (BBI) isolated, purified, cloned, and characterized from Maclura pomifera seeds (MpBBI), the first of this type from a species belonging to Moraceae family. MpBBI was purified to homogeneity by RP-HPLC, total RNA was extracted from seeds of M. pomifera, and the 3'RACE-PCR method was applied to obtain the cDNA, which was cloned and sequenced. Peptide mass fingerprinting (PMF) analysis showed correspondence between the in silico-translated protein and MpBBI, confirming that it corresponds to a new plant protease inhibitor. The obtained cDNA encoded a polypeptide of 65 residues and possesses 10 cysteine residues, with molecular mass of 7379.27, pI 6.10, and extinction molar coefficient of 9105 M-1 cm-1. MpBBI inhibits strongly trypsin with K i in the 10-10 M range and was stable in a wide array of pH and extreme temperatures. MpBBI comparative modeling was applied to gain insight into its 3D structure and highlighted some distinguishing features: (1) two non-identical loops, (2) loop 1 (CEEESRC) is completely different from any known BBI, and (3) the amount of disulphide bonds is also different from any reported BBI from dicot plants.
Collapse
Affiliation(s)
- Martín Indarte
- PHusisTherapeutics, 3210 Merryfield Row, San Diego, CA, 92121, USA
| | - Cristian M Lazza
- Centro de Investigación de Proteínas Vegetales, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 1900, La Plata, Argentina
| | - Diego Assis
- Departamento de Biofisica, Universidade Federal de São Paulo, Vila Clementino, São Paulo, 04044-020, Brazil
| | - Néstor O Caffini
- Centro de Investigación de Proteínas Vegetales, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 1900, La Plata, Argentina
| | - María A Juliano
- Departamento de Biofisica, Universidade Federal de São Paulo, Vila Clementino, São Paulo, 04044-020, Brazil
| | - Francesc X Avilés
- Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain
| | - Xavier Daura
- Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain
| | - Laura M I López
- Instituto de Ciencias de la Salud, Universidad Nacional Arturo Jauretche, 1888 Florencio Varela, Buenos Aires, Argentina.
- CITEC, Gonnet, B1897, Buenos Aires, Argentina.
| | - Sebastián A Trejo
- Laboratorio de Neurofisiología del Instituto Multidisciplinar de Biología Celular (IMBICE), La Plata, B1906APO, Buenos Aires, Argentina.
| |
Collapse
|
7
|
Cruz-Huerta E, Fernández-Tomé S, Arques MC, Amigo L, Recio I, Clemente A, Hernández-Ledesma B. The protective role of the Bowman-Birk protease inhibitor in soybean lunasin digestion: the effect of released peptides on colon cancer growth. Food Funct 2015; 6:2626-35. [PMID: 26132418 DOI: 10.1039/c5fo00454c] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
Lunasin is a naturally-occurring peptide demonstrating chemopreventive, antioxidant and anti-inflammatory properties. To exhibit these activities, orally ingested lunasin needs to survive proteolytic attack of digestive enzymes to reach target tissues in active form/s. Preliminary studies suggested the protective role of protease inhibitors, such as the Bowman-Birk inhibitor and Kunitz-trypsin inhibitor, against lunasin's digestion by both pepsin and pancreatin. This work describes in depth the behaviour of lunasin under conditions simulating the transit through the gastrointestinal tract in the absence or presence of soybean Bowman-Birk isoinhibitor 1 (IBB1) in both active and inactive states. By liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS), the remaining lunasin at the end of gastric and gastro-duodenal phases was quantified. Protection against the action of pepsin was independent of the amount of IBB1 present in the analyzed samples, whereas an IBB1 dose-dependent protective effect against trypsin and chymotrypsin was observed. Peptides released from lunasin and inactive IBB1 were identified by MS/MS. The remaining lunasin and IBB1 as well as their derived peptides could be responsible for the anti-proliferative activity against colon cancer cells observed for the digests obtained at the end of simulated gastrointestinal digestion.
Collapse
Affiliation(s)
- Elvia Cruz-Huerta
- Instituto de Investigación en Ciencias de la Alimentación (CIAL, CSIC-UAM CEI UAM+CSIC), Nicolás Cabrera, 9, 28049 Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
8
|
Utrilla MP, Peinado MJ, Ruiz R, Rodriguez-Nogales A, Algieri F, Rodriguez-Cabezas ME, Clemente A, Galvez J, Rubio LA. Pea (Pisum sativum L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis. Mol Nutr Food Res 2015; 59:807-19. [PMID: 25626675 DOI: 10.1002/mnfr.201400630] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 01/15/2015] [Accepted: 01/16/2015] [Indexed: 01/10/2023]
Abstract
SCOPE This study investigates the preventive effects of two pea (Pisum sativum) seed albumin extracts, either in the presence (pea seed extract [PSE]) or absence (albumin fraction from PSE [AF-PSE]) of soluble polysaccharides, in the dextran sodium sulfate (DSS) induced colitis in mice. METHODS AND RESULTS Male C57BL/6J mice were assigned to five groups: one noncolitic and four colitic. Colitis was induced by incorporating DSS (3.5%) in the drinking water for 4 days, after which DSS was removed. Treated groups received orally PSE (15 g/kg⋅day), or AF-PSE (1.5 g/kg⋅day), or pure soy Bowman-Birk inhibitor (BBI; 50 mg/kg⋅day), starting 2 wk before colitis induction, and maintained for 9 days after. All treated groups showed intestinal anti-inflammatory effect, evidenced by reduced microscopic histological damage in comparison with untreated colitic mice. The treatments ameliorated the colonic mRNA expression of different proinflammatory markers: cytokines, inducible enzymes, metalloproteinases, adhesion molecules, and toll-like receptors, as well as proteins involved in maintaining the epithelial barrier function. Furthermore, the administration of PSE, AF-PSE, or soy BBI restored bacterial counts, partially or totally, to values in healthy mice. CONCLUSION PSE and AF-PSE ameliorated DSS-induced damage to mice, their effects being due, at least partially, to the presence of active BBI.
Collapse
Affiliation(s)
- Ma Pilar Utrilla
- CIBER-EHD, Department of Pharmacology, ibs. GRANADA, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Clemente A, Arques MDC. Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents. World J Gastroenterol 2014; 20:10305-10315. [PMID: 25132747 PMCID: PMC4130838 DOI: 10.3748/wjg.v20.i30.10305] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 02/21/2014] [Accepted: 04/23/2014] [Indexed: 02/06/2023] Open
Abstract
Aberrant functioning of serine proteases in inflammatory and carcinogenic processes within the gastrointestinal tract (GIT) has prompted scientists to investigate the potential of serine protease inhibitors, both natural and synthetic, as modulators of their proteolytic activities. Protease inhibitors of the Bowman-Birk type, a major protease inhibitor family in legume seeds, which inhibit potently and specifically trypsin- and chymotrypsin-like proteases, are currently being investigated as colorectal chemopreventive agents. Physiologically relevant amounts of Bowman-Birk inhibitors (BBI) can reach the large intestine in active form due to their extraordinary resistance to extreme conditions within the GIT. Studies in animal models have proven that dietary BBI from several legume sources, including soybean, pea, lentil and chickpea, can prevent or suppress carcinogenic and inflammatory processes within the GIT. Although the therapeutic targets and the action mechanism of BBI have not yet been elucidated, the emerging evidence suggests that BBI exert their preventive properties via protease inhibition; in this sense, serine proteases should be considered as primary targets in early stages of carcinogenesis. The validation of candidate serine proteases as therapeutic targets together with the identification, within the wide array of natural BBI variants, of the most potent and specific protease inhibitors, are necessary to better understand the potential of this protein family as colorectal chemopreventive agents.
Collapse
|
10
|
Arques MC, Marín-Manzano MC, da Rocha LCB, Hernandez-Ledesma B, Recio I, Clemente A. Quantitative determination of active Bowman-Birk isoinhibitors, IBB1 and IBBD2, in commercial soymilks. Food Chem 2014; 155:24-30. [PMID: 24594149 DOI: 10.1016/j.foodchem.2014.01.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 11/28/2013] [Accepted: 01/10/2014] [Indexed: 12/27/2022]
Abstract
Naturally-occurring serine protease inhibitors of the Bowman-Birk family exert their potential chemopreventive and/or therapeutic properties via protease inhibition. In this study, we have quantified the amounts of active BBI isoinhibitors, IBB1 and IBBD2, in six commercial soymilks. By using cation exchange chromatography, the BBI isoinhibitors were isolated and their specific trypsin inhibitory activity was used to estimate their amounts in soymilk samples. IBB1 and IBBD2 concentrations ranged from 0.44 to 5.20 and 0.27 to 4.60 mg/100ml of soymilk, respectively; total BBI, considered as the sum of both isoinhibitors, ranged from 0.60 to 9.07 mg/100ml of soymilk. These data show that physiologically relevant amounts of active BBI are present in commercial soymilk and may exert potential health-promoting effects.
Collapse
Affiliation(s)
- M Carmen Arques
- Department of Nutrition, Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | - M Carmen Marín-Manzano
- Department of Nutrition, Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain
| | | | - Blanca Hernandez-Ledesma
- Department of Food Analysis and Bioactivity, Institute of Food Science (CIAL, CSIC-UAM), Nicolás Cabrera 9, 28049 Madrid, Spain
| | - Isidra Recio
- Department of Food Analysis and Bioactivity, Institute of Food Science (CIAL, CSIC-UAM), Nicolás Cabrera 9, 28049 Madrid, Spain
| | - Alfonso Clemente
- Department of Nutrition, Estación Experimental del Zaidín (CSIC), Profesor Albareda 1, 18008 Granada, Spain.
| |
Collapse
|
11
|
Clemente A, Carmen Marín-Manzano M, Jiménez E, Carmen Arques M, Domoney C. The anti-proliferative effect of TI1B, a major Bowman-Birk isoinhibitor from pea (Pisum sativum L.), on HT29 colon cancer cells is mediated through protease inhibition. Br J Nutr 2012; 108 Suppl 1:S135-44. [PMID: 22916809 DOI: 10.1017/s000711451200075x] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Bowman-Birk inhibitors (BBI) from legumes, such as soyabean, pea, lentil and chickpea, are naturally occurring plant protease inhibitors which have potential health-promoting properties within the mammalian gastrointestinal tract. BBI can survive both acidic conditions and the action of proteolytic enzymes within the stomach and small intestine, permitting significant amounts to reach the large intestine in active form to exert their reported anti-carcinogenic and anti-inflammatory properties. In a previous study, we reported the ability of a recombinant form of TI1B (rTI1B), representing a major BBI isoinhibitor from pea, to influence negatively the growth of human colorectal adenocarcinoma HT29 cells in vitro. In the present study, we investigate if this effect is related directly to the intrinsic ability of BBI to inhibit serine proteases. rTI1B and a novel engineered mutant, having amino acid substitutions at the P1 positions in the two inhibitory domains, were expressed in the yeast Pichia pastoris. The rTI1B proved to be active against trypsin and chymotrypsin, showing K i values at nanomolar concentrations, whereas the related mutant protein was inactive against both serine proteases. The proliferation of HT29 colon cancer cells was significantly affected by rTI1B in a dose-dependent manner (IC50 = 31 (sd 7) μm), whereas the inactive mutant did not show any significant effect on colon cancer cell growth. In addition, neither recombinant protein affected the growth of non-malignant colonic fibroblast CCD-18Co cells. These findings suggest that serine proteases should be considered as important targets in investigating the potential chemopreventive role of BBI during the early stages of colorectal carcinogenesis.
Collapse
Affiliation(s)
- Alfonso Clemente
- Department of Physiology and Biochemistry of Nutrition, Estación Experimental del Zaidín (CSIC), Professor Albareda 1, 18008 Granada, Spain
| | | | | | | | | |
Collapse
|
12
|
Bowman-Birk Inhibitor attenuates experimental autoimmune encephalomyelitis by delaying infiltration of inflammatory cells into the CNS. Immunol Res 2012; 51:145-52. [PMID: 22095543 DOI: 10.1007/s12026-011-8254-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Bowman-Birk Inhibitor (BBI), a serine protease inhibitor derived from soybeans, has anti-inflammatory properties and is able to suppress the development of central nervous system (CNS) autoimmunity in animal models. Experimental autoimmune encephalomyelitis (EAE), a widely used animal model of multiple sclerosis (MS), is characterized by breakdown of the blood-brain barrier and infiltration of inflammatory cells into the CNS, resulting in pathology. In this study, we observed that BBI-treated mice showed delayed onset of EAE and reduced disease severity compared to control mice. BBI-treated mice had fewer inflammatory cells in the CNS including significantly reduced numbers of Th1 and Th17 cells. In the periphery, BBI treatment suppressed the development of encephalitogenic Th1 and Th17 responses early on [day 7 post-immunization (p.i.)], while after disease onset (day 14 p.i.) BBI-treated mice had stronger Th responses, as determined by antigen-specific proliferation and cytokine production. These results demonstrate that BBI treatment temporarily suppressed the development of encephalitogenic responses, but these responses eventually attained normal magnitude. Given that BBI-treated mice exhibited stronger encephalitogenic responses in the periphery during clinically manifesting EAE, delayed disease onset, and reduced numbers of CNS-infiltrating cells, it appears likely that BBI impedes the exit of pathogenic Th1 and Th17 cells from lymphoid organs, thereby delaying their migration into the CNS.
Collapse
|
13
|
Xiao CW, Wood CM, Robertson P, Gilani GS. Protease inhibitor activities and isoflavone content in commercial soymilks and soy-based infant formulas sold in Ottawa, Canada. J Food Compost Anal 2012. [DOI: 10.1016/j.jfca.2011.10.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Dai H, Ciric B, Zhang GX, Rostami A. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. J Neuroimmunol 2012; 245:1-7. [PMID: 22365083 DOI: 10.1016/j.jneuroim.2012.01.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Revised: 12/29/2011] [Accepted: 01/12/2012] [Indexed: 11/26/2022]
Abstract
The Bowman-Birk inhibitor (BBI) is a soybean-derived serine protease inhibitor with anti-inflammatory properties. Experimental autoimmune encephalomyelitis (EAE) serves as an animal model of the central nervous system (CNS) inflammatory disorder multiple sclerosis (MS). EAE is mediated by Th1 and Th17 cells which migrate into the CNS and initiate inflammation directed against myelin components, resulting in CNS pathology and neurological clinical deficit. We have shown previously that oral treatment with BBI delays onset of EAE and reduces its severity. These beneficial effects were associated with an increase in IL-10 secretion by immune cells of BBI-treated mice. It is not known, however, whether this was a causal relationship or simply an epiphenomenon. In the present study we provide evidence that BBI regulates CD4+ T cell immune responses in EAE. BBI administration delayed the onset of EAE and reduced its severity in an IL-10-dependent manner, as BBI-mediated suppression of EAE was abrogated in IL-10 knockout mice. The beneficial effects were accompanied by reduced IFN-γ, IL-17 and increased IL-10 production, as well as increased Foxp3 expression. CD4+ T cells were the major source of IL-10 in the periphery and in the CNS during BBI treatment. Furthermore, BBI-treated mice had reduced numbers of infiltrated cells in the CNS, including Th17 cells, as compared with PBS-treated control animals. In conclusion, our data provide clear evidence for the essential role of IL-10 in BBI-mediated suppression in EAE, and indicate that BBI may be a promising candidate for the development of a novel MS therapy.
Collapse
Affiliation(s)
- Hong Dai
- Department of Neurology, Thomas Jefferson University, Jefferson Hospital for Neuroscience, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA
| | | | | | | |
Collapse
|
15
|
Capraro J, Clemente A, Rubio LA, Magni C, Scarafoni A, Duranti M. Assessment of the lupin seed glucose-lowering protein intestinal absorption by using in vitro and ex vivo models. Food Chem 2011. [DOI: 10.1016/j.foodchem.2010.10.073] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Sun LC, Yoshida A, Cai QF, Liu GM, Weng L, Tachibana K, Su WJ, Cao MJ. Mung bean trypsin inhibitor is effective in suppressing the degradation of myofibrillar proteins in the skeletal muscle of blue scad (Decapterus maruadsi). JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2010; 58:12986-12992. [PMID: 21090622 DOI: 10.1021/jf103526e] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Mung bean trypsin inhibitor (MBTI) of the Bowman-Birk family was purified to homogeneity with a molecular mass of approximately 9 kDa on tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 8887.25 Da as determined by matrix-assisted laser desorption/ionization-quadrupole ion trap-time-of-flight mass spectrometry (MALDI-QIT-TOF MS). Using blue scad myofibrillar proteins as targets, it was found that, in the absence of MBTI, proteolysis of myofibrillar proteins, especially myosin heavy chain (MHC), could be identified after incubation at 55 °C for 2 h, while in the presence of MBTI, with a final concentration of 25 ng/mL, proteolysis of these proteins was greatly suppressed even after incubation for 3 h. Although cysteine proteinase inhibitor E-64 was also effective in preventing protein degradation, inhibitors for metallo- and asparatic proteinases did not reveal obvious inhibitory effects. Our present results strongly suggested that the naturally occurring legume bean seed protein MBTI can be used as an effective additive in preventing marine fish blue scad surimi gel softening, which is quite possibly caused by myofibril-bound serine proteinase (MBSP).
Collapse
Affiliation(s)
- Le-Chang Sun
- College of Biological Engineering, Jimei University, Jimei, Xiamen, Fujian 361021, China
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Muricken DG, Gowda LR. Molecular engineering of a small trypsin inhibitor based on the binding loop of horsegram seed Bowman-Birk inhibitor. J Enzyme Inhib Med Chem 2010; 26:553-60. [DOI: 10.3109/14756366.2010.536158] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Deepa G. Muricken
- Department of Protein Chemistry and Technology, Central Food Technological Research Institute, Council of Scientific and Industrial Research (CSIR), Mysore, India
| | - Lalitha R. Gowda
- Department of Protein Chemistry and Technology, Central Food Technological Research Institute, Council of Scientific and Industrial Research (CSIR), Mysore, India
| |
Collapse
|
18
|
Clemente A, Moreno FJ, Marín-Manzano MDC, Jiménez E, Domoney C. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Mol Nutr Food Res 2010; 54:396-405. [PMID: 19885848 DOI: 10.1002/mnfr.200900122] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Bowman-Birk inhibitors (BBI) from soybean and related proteins are naturally occurring protease inhibitors with potential health-promoting properties within the gastrointestinal tract. In this work, we have investigated the effects of soybean BBI proteins on HT29 colon adenocarcinoma cells, compared with non-malignant colonic fibroblast CCD-18Co cells. Two major soybean isoinhibitors, IBB1 and IBBD2, showing considerable amino acid sequence divergence within their inhibitory domains, were purified in order to examine their functional properties, including their individual effects on the proliferation of HT29 colon cancer cells. IBB1 inhibited both trypsin and chymotrypsin whereas IBBD2 inhibited trypsin only. Despite showing significant differences in their enzyme inhibitory properties, the median inhibitory concentration values determined for IBB1 and IBBD2 on HT29 cell growth were not significantly different (39.9+/-2.3 and 48.3+/-3.5 microM, respectively). The cell cycle distribution pattern of HT29 colon cancer cells was affected by BBI treatment in a dose-dependent manner, with cells becoming blocked in the G0-G1 phase. Chemically inactive soybean BBI had a weak but non-significant effect on the proliferation of HT29 cells. The anti-proliferative properties of BBI isoinhibitors from soybean reveal that both trypsin- and chymotrypsin-like proteases involved in carcinogenesis should be considered as potential targets of BBI-like proteins.
Collapse
Affiliation(s)
- Alfonso Clemente
- Department of Physiology and Biochemistry of Nutrition, Estación Experimental del Zaidín (CSIC), Granada, Spain.
| | | | | | | | | |
Collapse
|
19
|
Caccialupi P, Ceci LR, Siciliano RA, Pignone D, Clemente A, Sonnante G. Bowman-Birk inhibitors in lentil: Heterologous expression, functional characterisation and anti-proliferative properties in human colon cancer cells. Food Chem 2010. [DOI: 10.1016/j.foodchem.2009.11.051] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
20
|
Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, Dwyer JT, Kim YS, Pontzer CH, Starke-Reed PE, Weaver CM. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr 2010; 140:1192S-1204S. [PMID: 20392880 PMCID: PMC2869505 DOI: 10.3945/jn.110.121830] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The NIH sponsored a scientific workshop, "Soy Protein/Isoflavone Research: Challenges in Designing and Evaluating Intervention Studies," July 28-29, 2009. The workshop goal was to provide guidance for the next generation of soy protein/isoflavone human research. Session topics included population exposure to soy; the variability of the human response to soy; product composition; methods, tools, and resources available to estimate exposure and protocol adherence; and analytical methods to assess soy in foods and supplements and analytes in biologic fluids and other tissues. The intent of the workshop was to address the quality of soy studies, not the efficacy or safety of soy. Prior NIH workshops and an evidence-based review questioned the quality of data from human soy studies. If clinical studies are pursued, investigators need to ensure that the experimental designs are optimal and the studies properly executed. The workshop participants identified methodological issues that may confound study results and interpretation. Scientifically sound and useful options for dealing with these issues were discussed. The resulting guidance is presented in this document with a brief rationale. The guidance is specific to soy clinical research and does not address nonsoy-related factors that should also be considered in designing and reporting clinical studies. This guidance may be used by investigators, journal editors, study sponsors, and protocol reviewers for a variety of purposes, including designing and implementing trials, reporting results, and interpreting published epidemiological and clinical studies.
Collapse
Affiliation(s)
- Marguerite A. Klein
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907,To whom correspondence should be addressed. E-mail:
| | - Richard L. Nahin
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Mark J. Messina
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Jeanne I. Rader
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Lilian U. Thompson
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Thomas M. Badger
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Johanna T. Dwyer
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Young S. Kim
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Carol H. Pontzer
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Pamela E. Starke-Reed
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| | - Connie M. Weaver
- Office of Dietary Supplements,; National Center for Complementary and Alternative Medicine,; National Cancer Institute, and Division of Nutrition Research Coordination, National Institutes of Health, Bethesda, MD 20892; Department of Nutrition, Loma Linda University, Loma Linda, CA 92350; Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD 20740; Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 3E2; Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72202; Department of Foods and Nutrition, Purdue University, West Lafayette, IN 47907
| |
Collapse
|